(Total Views: 479)
Posted On: 02/09/2020 10:26:48 AM
Post# of 154977
ANCOUVER, Washington, Jan. 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the acceptance of an abstract detailing the advantages of the CCR5 antibody, leronlimab, to prevent macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) at the Keystone Symposia on HIV Pathogenesis and Cure in Keystone, Colorado from March 22-26, 2020.
Details of the oral presentation are as follows:
Presentation Title: Antibody-Mediated CCR5 Blockade Recapitulates the CCR5 Deficiency-Mediated Protection from Sexual HIV Acquisition
Presenter: Xiao Lan Chang, Oregon Health & Science University
Presentation Date and Time: Thursday, March 26, 2020 from 2:30 p.m. MT – 4:30 p.m. MT
Additional details can be found on the conference website.
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the acceptance of an abstract detailing the advantages of the CCR5 antibody, leronlimab, to prevent macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) at the Keystone Symposia on HIV Pathogenesis and Cure in Keystone, Colorado from March 22-26, 2020. Details of the oral presentation are as follows:
Presentation Title: Antibody-Mediated CCR5 Blockade Recapitulates the CCR5 Deficiency-Mediated Protection from Sexual HIV Acquisition
Presenter: Xiao Lan Chang, Oregon Health & Science University
Presentation Date and Time: Thursday, March 26, 2020 from 2:30 p.m. MT – 4:30 p.m. MT
Additional details can be found on the conference website.
(0)
(0)
My comments are just my opinions and should NOT be taken as investment advice.
